Ibrx stock forecast 2025

Operations: Focused on novel therapeutics for MASH, Madrigal Pharmaceuticals operates within the biopharmaceutical sector in the United States. ImmunityBio is doing well on the financial side, as in Q3 2024, it made $6.0 million in product revenue, six times more than last quarter and outperforming analysts’ predictions. Starting January 2025, ANKTIVA has a permanent J-code, making it easier for Medicare and VA patients to get covered. ImmunityBio, Inc. (NASDAQ:IBRX) is also expanding globally, having applied for approval in the UK’s MHRA last November and planning for an EMA in the EU soon. Analysts tracking IBRX stock forecast 2025 anticipate potential upside driven by clinical pipeline progress, with consensus estimates hovering around a possible $4.50–$6.00 range if trial outcomes remain favorable. Market sentiment is currently risk-on for biotech plays in niche immunotherapy.